A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient

Hyperkalemia contributes to significant mortality and limits the use of cardioprotective and renoprotective renin–angiotensin–aldosterone blockers. Current therapies are poorly tolerated and not always effective. Here we conducted a phase 2 randomized, double-blind, placebo-controlled dose-escalatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Ash, Stephen R, Singh, Bhupinder, Lavin, Philip T, Stavros, Fiona, Rasmussen, Henrik S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4526769/
https://www.ncbi.nlm.nih.gov/pubmed/25651363
http://dx.doi.org/10.1038/ki.2014.382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4526769/
https://www.ncbi.nlm.nih.gov/pubmed/25651363
http://dx.doi.org/10.1038/ki.2014.382

Ejemplares similares